Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 611 active trials
51 drugs · 1,372 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 14 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Methotrexate | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 14, 2018 |
| Mocetinostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 7, 2016 |
| Radiation Therapy | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Feb 10, 2017 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2014-11 |
| Anti-PD-L1 Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 8, 2026 |
| Avapritinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 20, 2021 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Dabrafenib/Trametinib Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 1, 2024 |
| Paclitaxel Liposome | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 14, 2023 |
| Platinum Compound | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 6, 2025 |
| Rezatapopt | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 29, 2020 |
| Teniposide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 1, 2024 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 24 | 0 | — | — | 2002-04 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 20 | 0 | — | — | 2004-05 |
| Azacitidine | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2000-05 |
| Enzastaurin | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2005-03 |
| Sirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2004-10 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2002-07 |
| Luminespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2010-10 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2009-03 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2002-02 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2011-05 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2008-10 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2004-12 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 1999-09 |
| Decitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 1999-10 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2003-11 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2000-06 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2010-02 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2010-09 |
| Cabazitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2012-03 |
| Lenalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2005-03 |
| Pegargiminase | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-01 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-11 |
| Conatumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2008-01 |
| Exemestane | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2012-05 |
| Ganitumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 2, 2008 |
| Ibrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2015-03 |
| Linsitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Mar 4, 2011 |
| Pictilisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2009-09 |
| Pralatrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-07 |
| Prexasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2010-02 |
| Retaspimycin Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-01 |
| Rucaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Dec 24, 2018 |
| Tyrosine Kinase Inhibitor | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Mar 10, 2017 |
| Vinflunine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-10 |
| Abiraterone | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 3, 2021 |
| Abiraterone Acetate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 17, 2016 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Nov 30, 2008 |
| Alpelisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 20, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.